Enavate Sciences logo

Enavate Sciences

North America, New York, United States, New York

Description

Enavate Sciences is committed to invest in and support the strategic growth of innovative therapeutic and enabling technology companies.

Investor Profile

Enavate Sciences has made 15 investments, with 5 in the past 12 months and 67% as lead.

Stage Focus

  • Series B (47%)
  • Series C (20%)
  • Post Ipo Equity (13%)
  • Series Unknown (7%)
  • Series A (7%)
  • Private Equity (7%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Biopharma
  • Therapeutics
  • Health Care
  • Medical
  • Pharmaceutical
  • Life Science
  • Genetics
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Enavate Sciences frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 2
OrbiMed
North America, New York, United States, New York
Co-Investments: 4
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 3
Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 3
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 4
Longitude Capital
North America, California, United States, Menlo Park
Co-Investments: 5
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 3
Sanofi Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2

What are some of recent deals done by Enavate Sciences?

Normunity

New Haven, Connecticut, United States

Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.

BiotechnologyMedicalOncologyTherapeutics
Series BJan 13, 2025
Amount Raised: $75,000,000
Aviceda Therapeutics

Cambridge, Massachusetts, United States

Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.

BiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics
Series CJan 7, 2025
Amount Raised: $207,500,000
OrsoBio

Palo Alto, California, United States

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

BiopharmaBiotechnologyHealth CareMedicalTherapeutics
Series BSep 6, 2024
Amount Raised: $67,000,000
Zenas BioPharma

Waltham, Massachusetts, United States

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

BiopharmaHealth CarePharmaceutical
Series CMay 7, 2024
Amount Raised: $200,000,000
BridgeBio Oncology Therapeutics

Palo Alto, California, United States

BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.

BiopharmaTherapeutics
Series UnknownMay 2, 2024
Amount Raised: $200,000,000
Sionna Therapeutics

Natick, Massachusetts, United States

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

BiotechnologyGeneticsHealth CareMedicalPharmaceuticalTherapeutics
Series CMar 6, 2024
Amount Raised: $182,000,000
Sudo Biosciences

Carmel, Indiana, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

BiopharmaBiotechnologyHealth CareLife ScienceMedical
Series BFeb 13, 2024
Amount Raised: $30,000,000
Graviton Bioscience

New York, New York, United States

Biotechnology, clinical stage, CNC, autoimmune, fibrotic indications

BiotechnologyTherapeutics
Private EquityJan 2, 2024
Amount Raised: $24,999,998
Sudo Biosciences

Carmel, Indiana, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

BiopharmaBiotechnologyHealth CareLife ScienceMedical
Series BDec 20, 2023
Amount Raised: $116,000,000
OrsoBio

Palo Alto, California, United States

OrsoBio develops therapies to treat severe metabolic disorders, including type 2 diabetes, and other conditions.

BiopharmaBiotechnologyHealth CareMedical
Series ANov 7, 2023
Amount Raised: $60,000,000